It has been observed that when liver cancer cells lacking the RB protein are exposed to sorafenib, their cell mortality is 2∼3 times higher than that of liver cancer cells with normal RB protein levels, suggesting that evaluating the RB status could be used to judge the drug resistance of HCC patients to sorafenib (Louandre et al., 2015). This evidence concerns the gene RB1 and hepatocellular carcinoma.